Antipodes Partners LTD Nuvalent, Inc. Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Nuvalent, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 479 shares of NUVL stock, worth $40,341. This represents 0.0% of its overall portfolio holdings.
Number of Shares
479
Previous 540
11.3%
Holding current value
$40,341
Previous $38,000
5.26%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
225Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.52 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$444 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$381 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$255 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$151 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.62B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...